Moffitt Cancer Center | Strategic Alliance Partners

Analyze risks and complications associated with allo-HSCT, including graft-versus-host disease, infections, relapse, and regimen-related toxicities.

This presentation will detail the supportive therapies and interventions provided to patients before, during, and after undergoing allo-HSCT. The speaker will also discuss management of treatment side effects and comorbidities to optimize patient outcomes.

Delve into the pre-transplant conditioning regimens such as chemotherapy and radiation used to prepare and immunosuppress patients to prevent graft rejection prior to allogeneic hematopoietic stem cell transplantation.

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.

Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).

Iman Imanirad, MD, medical oncologist, gastrointestinal oncology, Moffitt Cancer Center, discusses the management of toxicities associated with standard-of-care encorafenib plus cetuximab for patients with previously treated microsatellite stable BRAF V600E metastatic colorectal cancer.

Richard Kim, MD, discusses ongoing and planned research at Moffitt Cancer Center in patients with hepatocellular carcinoma.

A panel of experts discuss how to choose bispecific T-cell engagers as third-line and beyond therapy for FL.

Laurie Sehn, MD, discusses recent data on zanubrutinib, a BTK inhibitor, as third-line and beyond therapy for FL.

Richard Kim, MD, discusses selecting between frontline immunotherapy-based regimens in patients with hepatocellular carcinoma.

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.

Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from studies such as the 6-year follow-up of ELEVATE-TN and the extended follow-up from SEQUOIA.

Ariel Grajales-Cruz, MD, discusses real-world safety and efficacy outcomes with teclistamab in select patients with relapsed/refractory multiple myeloma.

Ciara Freeman, MD, PhD, outlines an analysis conducted to identify factors linked to CAR T-cell therapy response in patients with hematologic malignancies.

Michael Jain, MD, discusses the importance of evaluating the impact of lymphoma-associated CD39-positive T cells on CAR T-cell phenotypes.

Peter Martin, MD, discusses recent data on tazemetostat, an EZH2 inhibitor, as third-line and beyond therapy for FL.

Matthew Lunning, DO, discusses recent data on bispecific T-cell engagers as third-line and beyond therapy for FL.

Rachid Baz, MD, discusses the use of idecabtagene vicleucel vs standard regimens in triple-class–exposed, relapsed/refractory multiple myeloma.

Andrew Kuykendall, MD, discusses the efficacy of pelabresib plus ruxolitinib in patients with JAK inhibitor–naive myelofibrosis.

David A. Sallman, MD, discusses the rationale for conducting a phase 2, multi-institutional, investigator-initiated clinical trial on the use of fedratinib in patients with myelodysplastic syndromes/myeloproliferative neoplasm overlap syndromes and chronic neutrophilic leukemia.

Richard Kim, MD, discusses a case study of a patient who presented with hepatocellular carcinoma, detailing the steps that were taken upon diagnosis.

Bijal Shah, MD, discusses recent data on CAR T-cell therapy as third-line and beyond treatment for FL.

Experts on follicular lymphoma discuss second-line treatment options available for patients.

A panel of experts review latest data from ASH 2023 on approved and emerging therapies in frontline FL.

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

Experts on follicular lymphoma discuss first-line treatment options available for patients.

Experts discuss what role allogeneic transplants play in hematologic malignancies, specifically in AML and ALL.

Andrew Kuykendall, MD, discusses the current role of JAK inhibitors in myelofibrosis, the importance of chronic graft-vs-host disease awareness in patients with myeloid malignancies receiving transplant, and unmet needs for patients with chronic myelomonocytic leukemia.

Arnold Etame, MD, PhD, discusses the effects of a patient’s socioeconomic status on the cancer treatment options they receive.